|
Press Releases |
|
 |
|
Wednesday, May 9, 2018 |
|
Helsinn Group announces the launch of the IV formulation of AKYNZEO(R) (fosnetupitant/palonosetron) in the United States |
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the intravenous formulation of AKYNZEO(R) (a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) for injection has been launched in the United States by its U.S. subsidiary, Helsinn Therapeutics (U.S.), Inc.. more info >> |
|
Friday, April 20, 2018 |
|
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO(R) (fosnetupitant/ palonosetron) in the United States |
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the U.S. Food and Drug Administration (FDA) has approved the intravenous formulation of AKYNZEO(R) (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing CINV. more info >> |
|
Tuesday, April 17, 2018 |
|
Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy |
Taiho Pharmaceutical Co., Ltd., a Japanese R&D-driven specialty pharma focused on oncology and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announce that they are collaborating on the development of an investigational highly-selective RET inhibitor TAS0286/HM05, being evaluated in non-small cell lung cancer and other carcinomas. more info >> |
|
Wednesday, March 28, 2018 |
|
Helsinn Healthcare S.A.: Winners of the inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced |
Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, today announced that Lorenzo Pradella of GreenBone Ortho, srl and Gitte Pedersen of Genomic Expression, Inc. have been chosen as winners of the first ever Lyfebulb-Helsinn Innovation Awards in Oncology. more info >> |
|
Friday, March 2, 2018 |
|
Helsinn Healthcare S.A.: Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology |
Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, today announce the names of the eleven companies launched by patient entrepreneurs who are chosen as finalists for the Lyfebulb-Helsinn Innovation Summit & Award in Oncology. more info >> |
|
Tuesday, October 17, 2017 |
|
Helsinn Pharmaceuticals (Beijing) Co. Ltd. Opens Office in Shanghai, China |
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces the approval of Helsinn Pharmaceuticals (Beijing) Co. Ltd., Shanghai branch, on August 7, 2017 by the Shanghai Administration for Industry and Commerce with a 30-year term. The full address and contact details of the Shanghai branch are found at the end of this announcement. more info >> |
|
Friday, September 9, 2016 |
|
Helsinn and PatientsLikeMe Announce Results of NSCLC Patient Survey on Weight Loss |
Helsinn Therapeutics (U.S.) Inc., the pharmaceutical group focused on building quality cancer care, and patient network PatientsLikeMe have unveiled findings from an online survey that captured experiences and insights about unintended weight loss and its burden among 95 patients living with non-small cell lung cancer. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
SAPPE Makes a Global Splash in the Beverage Market, Unveils Global Campaign "Life's too Short, You Gotta Chew" at THAIFEX - ANUGA ASIA 2025
May 28, 2025 18:00 HKT/SGT
|
|
|
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
May 28, 2025 17:45 JST
|
|
|
Modern Dental Group's Thai Subsidiary Hexa Ceram Held 30th Anniversary Celebration and Dental Symposium
May 28, 2025 16:44 HKT/SGT
|
|
|
現代牙科集團泰國公司Hexa Ceram舉辦三十周年慶典暨牙科論壇
May 28, 2025 16:30 HKT/SGT
|
|
|
现代牙科集团泰国公司Hexa Ceram举办三十周年庆典暨牙科论坛
May 28, 2025 16:12 HKT/SGT
|
|
|
三菱重工、2024事業計画推進状況について発表
May 28, 2025 16:05: JST
|
|
|
SAPPE Makes a Global Splash in the Beverage Market, Unveils Global Campaign "Life's too Short, You Gotta Chew" at THAIFEX - ANUGA ASIA 2025
May 28, 2025 15:00: JST
|
|
|
GK Software becomes a Fujitsu company
May 28, 2025 15:33 JST
|
|
|
GMG Announces Internal G(R) Lubricant Testing Results Showing 10% Fuel Savings and 33% Reduction in Particulate Emissions
May 28, 2025 08:29 HKT/SGT
|
|
|
Spotlight: Sunny Nandwani, Founder & CEO, Acuver Consulting Inc.
May 27, 2025 22:30 HKT/SGT
|
|
|
聯想控股旗下君聯資本及聯想之星共同投資企業派格生物醫藥在港交所成功上市
May 27, 2025 22:10 HKT/SGT
|
|
|
联想控股旗下君联资本及联想之星共同投资企业派格生物医药在港交所成功上市
May 27, 2025 21:41 HKT/SGT
|
|
|
Top Business and Policy Leaders to Convene at CGS International's ASEAN Business Forum 2025 to Scale Intra-ASEAN and International Trade and Investment
May 27, 2025 18:00: JST
|
|
|
Top Business and Policy Leaders to Convene at CGS International's ASEAN Business Forum 2025 to Scale Intra-ASEAN and International Trade and Investment
May 27, 2025 17:00 HKT/SGT
|
|
|
AI and Agentic AI Take Center Stage as Customer Experience Live Show Middle East 2025 Charts the Future of CX in the region
May 27, 2025 16:09 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|